SG10201810450QA - Organoarsenic compounds and methods for the treatment of cancer - Google Patents

Organoarsenic compounds and methods for the treatment of cancer

Info

Publication number
SG10201810450QA
SG10201810450QA SG10201810450QA SG10201810450QA SG10201810450QA SG 10201810450Q A SG10201810450Q A SG 10201810450QA SG 10201810450Q A SG10201810450Q A SG 10201810450QA SG 10201810450Q A SG10201810450Q A SG 10201810450QA SG 10201810450Q A SG10201810450Q A SG 10201810450QA
Authority
SG
Singapore
Prior art keywords
cancer
treatment
methods
organoarsenic compounds
organoarsenic
Prior art date
Application number
SG10201810450QA
Other languages
English (en)
Inventor
Brian Eric Schwartz
Jonathan Lewis
Philip B Komarnitsky
Original Assignee
Solasia Pharma K K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solasia Pharma K K filed Critical Solasia Pharma K K
Publication of SG10201810450QA publication Critical patent/SG10201810450QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG10201810450QA 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer SG10201810450QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18951108P 2008-08-20 2008-08-20

Publications (1)

Publication Number Publication Date
SG10201810450QA true SG10201810450QA (en) 2018-12-28

Family

ID=41707414

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201810450QA SG10201810450QA (en) 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer
SG10201403869TA SG10201403869TA (en) 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer
SG10201810449XA SG10201810449XA (en) 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201403869TA SG10201403869TA (en) 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer
SG10201810449XA SG10201810449XA (en) 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer

Country Status (19)

Country Link
US (4) US20110269697A1 (zh)
EP (2) EP2321012B1 (zh)
JP (5) JP5933896B2 (zh)
KR (3) KR20180103194A (zh)
CN (2) CN104800828A (zh)
AU (1) AU2009282972A1 (zh)
BR (1) BRPI0918407A2 (zh)
CA (1) CA2734650A1 (zh)
DK (2) DK3388111T3 (zh)
ES (2) ES2703740T3 (zh)
HK (2) HK1254607A1 (zh)
IL (1) IL211153A0 (zh)
MX (1) MX2011001800A (zh)
NZ (1) NZ591181A (zh)
PT (2) PT3388111T (zh)
RU (1) RU2534606C2 (zh)
SG (3) SG10201810450QA (zh)
WO (1) WO2010021928A1 (zh)
ZA (1) ZA201101216B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160086960A (ko) * 2013-12-05 2016-07-20 솔레이지아 파마 가부시키가이샤 암 치료를 위한 화합물 및 방법
CN104151397A (zh) * 2014-07-03 2014-11-19 北京大学 一类新型三硫杂二环有机砷化物及其合成方法和在抗肿瘤领域里的应用
JP6413969B2 (ja) * 2015-07-29 2018-10-31 住友金属鉱山株式会社 日射遮蔽体形成用分散液および当該分散液を用いた日射遮蔽体
WO2019220961A1 (ja) * 2018-05-18 2019-11-21 ソレイジア・ファーマ株式会社 ダリナパルシンのアルカリ金属塩及び／又は無機酸付加塩の結晶型及びその製剤
US11998654B2 (en) 2018-07-12 2024-06-04 Bard Shannon Limited Securing implants and medical devices
CN113408945B (zh) * 2021-07-15 2023-03-24 广西中烟工业有限责任公司 一种烤烟纯度的检测方法、装置、电子设备及存储介质

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US234972A (en) 1880-11-30 William ennis
US761900A (en) 1904-03-05 1904-06-07 Newton Jefferson Norman Flux compound.
US2349729A (en) 1940-08-24 1944-05-23 Parke Davis & Co Therapeutic arsenic preparation
DE69842094D1 (de) 1997-10-15 2011-02-17 Polarx Biopharmaceuticals Inc Zusammensetzungen und Verfahren zur Behandlung primärer und metastatischer Erkrankungen mithilfe Arsentrioxid
ID25622A (id) 1997-11-10 2000-10-19 Sloan Kettering Inst Cancer Proses untuk memproduksi formulasi arsenat trioksida dan metoda untuk mengobati kanker dengan menggunakan arsenat trioksida atau melarsoprol
CN1233476A (zh) 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
EP1002537A1 (en) 1998-10-30 2000-05-24 Assistance Publique, Hopitaux De Paris Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma
US6191123B1 (en) 1999-03-19 2001-02-20 Parker Hughes Institute Organic-arsenic compounds
AU2001253919B2 (en) 2000-04-26 2006-12-14 Government Of The United States, D/B/A Department Of Veterans Affairs Administration of a thiol-based chemoprotectant compound
DE10132625A1 (de) 2001-07-05 2003-01-23 Oce Printing Systems Gmbh Verfahren, Computerprogrammprodukt und Gerätesystem zum visuellen Überprüfen von Bilddaten
US6911471B2 (en) * 2002-01-07 2005-06-28 The Texas A&M University System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
TW201440760A (zh) * 2004-07-16 2014-11-01 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物
AU2006285329B2 (en) 2005-07-29 2012-10-04 Solasia Pharma K.K. Compounds and methods for the treatment of cancer
CN104109177A (zh) * 2006-01-13 2014-10-22 得克萨斯州A&M大学系统 用于治疗癌症的化合物和方法
TW200829261A (en) 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
WO2009011893A2 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Treatments of b-cell proliferative disorders
EP2178370A4 (en) * 2007-07-17 2011-01-12 Zalicus Inc COMBINATIONS FOR THE TREATMENT OF PROLIFERATIVE B-CELL DISEASES
WO2009061373A1 (en) * 2007-11-02 2009-05-14 Ziopharm Oncology, Inc. Combination therapy with organic arsenicals
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders

Also Published As

Publication number Publication date
DK3388111T3 (da) 2021-12-06
ES2901426T3 (es) 2022-03-22
JP2014148552A (ja) 2014-08-21
JP2017002081A (ja) 2017-01-05
EP2321012A4 (en) 2011-10-05
WO2010021928A1 (en) 2010-02-25
EP2321012A1 (en) 2011-05-18
JP5976036B2 (ja) 2016-08-23
HK1212218A1 (zh) 2016-06-10
JP6315841B2 (ja) 2018-04-25
PT3388111T (pt) 2021-12-23
ES2703740T3 (es) 2019-03-12
RU2011110392A (ru) 2012-09-27
US20150231107A1 (en) 2015-08-20
US20110269697A1 (en) 2011-11-03
AU2009282972A1 (en) 2010-02-25
US11324714B2 (en) 2022-05-10
DK2321012T3 (en) 2018-12-03
HK1254607A1 (zh) 2019-07-26
JP5933896B2 (ja) 2016-06-15
MX2011001800A (es) 2011-04-04
CN104800828A (zh) 2015-07-29
RU2534606C2 (ru) 2014-11-27
US20210038556A1 (en) 2021-02-11
US10842769B2 (en) 2020-11-24
JP2018039853A (ja) 2018-03-15
ZA201101216B (en) 2011-10-26
US11324713B2 (en) 2022-05-10
JP2012500271A (ja) 2012-01-05
IL211153A0 (en) 2011-04-28
SG10201810449XA (en) 2018-12-28
BRPI0918407A2 (pt) 2015-11-24
EP2321012B1 (en) 2018-10-10
JP2015120755A (ja) 2015-07-02
EP3388111B1 (en) 2021-09-29
KR20110058818A (ko) 2011-06-01
SG10201403869TA (en) 2014-10-30
KR20180103194A (ko) 2018-09-18
CN102149432A (zh) 2011-08-10
CA2734650A1 (en) 2010-02-25
NZ591181A (en) 2012-09-28
KR20170103023A (ko) 2017-09-12
PT2321012T (pt) 2019-01-11
US20210038557A1 (en) 2021-02-11
EP3388111A1 (en) 2018-10-17

Similar Documents

Publication Publication Date Title
SG10201810449XA (en) Organoarsenic compounds and methods for the treatment of cancer
WO2008079339A3 (en) Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
MX2009005649A (es) Tratamiento para mieloma multiple.
TW200744586A (en) Therapeutic compounds
WO2010093849A3 (en) Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
MXPA05009694A (es) Metodos para mejorar la calidad de la piel.
BRPI0413746A (pt) composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo
NZ580226A (en) Dimer compounds as inhibitors of iap
WO2009026176A3 (en) Antiinfective flavononol compounds and methods of use thereof
GEP20125643B (en) Aurora kinase modulators and method of using same
BRPI0413740A (pt) composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo
HK1085675A1 (en) Anticancer compounds
NZ610378A (en) Lipoyl compounds and their use for treating ischemic injury
TW200510317A (en) Caspase inhibitors and uses thereof
TW200613292A (en) Benzothiazolium compounds
UA107562C2 (uk) Спосіб лікування псоріазу
EA200701852A1 (ru) Производные аминокислот
EA201170344A1 (ru) Азаиндольные ингибиторы iap
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
IL165259A0 (en) Compounds useful in the treatment of anthraxa and inhibiting lethal factor
TW200600084A (en) Anti-coronavirus compounds
ATE437642T1 (de) Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины
NZ591837A (en) Amino acid derivative